Gentian Diagnostics strengthens commercial capabilities with key appointments

28 Mar 2025 10:30 CET

Moss 28 March, 2025

Gentian Diagnostics ASA, a fast growing developer and manufacturer of diagnostic
tests, is excited to announce two strategic appointments that will enhance its
commercial capabilities and support long-term growth.

Markus Jaquemar, previously the CCO of Gentian, has been appointed as Chief
Growth Officer, effective March 2025. In this new role, Markus will focus on
business development, shaping Gentian’s long-term strategy, and leading growth
initiatives, including exploring new partnerships, technologies, and market
expansions. With over 30 years of experience in life science and diagnostics
commercialization and marketing, Markus brings a wealth of expertise to the
position. Prior to joining Gentian in 2020, he held various marketing, sales,
and business management roles at Beckman Coulter, Agilent Technologies, and
Becton Dickinson.

Additionally, we are pleased to welcome Hanne Kjellevold Kristiansen as Vice
President, Commercial. Hanne joins Gentian from Siemens Healthineers, where she
held several positions of increasing responsibility in both Norway and the USA,
most recently serving as Country Sales Lead for Siemens Healthineers diagnostics
division in Norway. With over 20 years of industry experience, Hanne has also
worked for companies such as Axis-Shield, GE Healthcare, and Dade Behring. She
holds degrees in Biomedical Engineering and Business Administration. Hanne’s
extensive experience and skills will be instrumental in supporting Gentian’s
ambitions for double-digit profitable growth, particularly in the US market. She
will also lead the commercial team in preparation for the anticipated 2026
launch of Gentian’s late-stage pipeline asset, the first-in-class NT-proBNP
heart failure marker on clinical chemistry platforms.

These appointments underscore Gentian’s commitment to driving innovation and
expanding its market presence globally.

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for
better treatment decisions. Gentian’s expertise and focus lies within
immunoassays, specifically for infections, inflammation, kidney disease and
congestive heart failure. By converting existing and clinically relevant
biomarkers to the most efficient, high-throughput analysers, the company
contributes to saving costs and protecting life. Gentian Diagnostics is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

More information:
Access the news on Oslo Bors NewsWeb site